Physician profile
Mark C Pluym
NPI 1942597489
$8,258.60
in general payments reported to CMS, 2019-2025
40 companies · $366 in 2025
The $366 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,063 · 2020: $230 · 2021: $721 · 2022: $1,977 · 2023: $2,218 · 2024: $1,683 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,194 · Education: $73.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,194.24 |
| Education | $73.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,761.08 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $903.15 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Genzyme Corporation | $766.69 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $719.52 | 2021-2024 | Dupixent |
| Glaxosmithkline, LLC. | $583.98 | 2019-2023 | Nucala |
| Amgen INC. | $448.13 | 2019-2024 | Enbrel, Tavneos, Otezla |
| Mylan Specialty L.P. | $434.67 | 2019-2024 | Yupelri |
| Janssen Biotech, INC. | $399.27 | 2019-2023 | Simponi Aria, Remicade, Simponi |
| Genentech USA, INC. | $331.04 | 2019-2025 | Xolair |
| Insmed, INC. | $330.13 | 2022-2025 | Arikayce |
| Ucb, INC. | $193.19 | 2023-2024 | Cimzia, Bimzelx |
| Electromed, INC. | $183.96 | 2021-2024 | Smartvest |
| Philips North America LLC | $161.90 | 2019-2025 | (8874) Incourage, Encore, (Ak6) Vest Therapy |
| Abbvie INC. | $153.78 | 2019-2024 | |
| Lilly USA, LLC | $121.12 | 2019-2023 | Taltz |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pluym listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.